1,6-dimethyl-2,3,4,6-tetrahydropyrido[3,4-b]pyrazin-5(1H)-one

ID: ALA5274345

Chembl Id: CHEMBL5274345

Max Phase: Preclinical

Molecular Formula: C9H13N3O

Molecular Weight: 179.22

Names and Identifiers

Canonical SMILES:  CN1CCNc2c1ccn(C)c2=O

Standard InChI:  InChI=1S/C9H13N3O/c1-11-6-4-10-8-7(11)3-5-12(2)9(8)13/h3,5,10H,4,6H2,1-2H3

Standard InChI Key:  DOHCVSNORATRFD-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA5274345

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 179.22

Molecular Weight (Monoisotopic): 179.1059

AlogP: 0.25

#Rotatable Bonds: ┄

Polar Surface Area: 37.27

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 4.20

CX LogP: -0.60

CX LogD: -0.60

Aromatic Rings: 1

Heavy Atoms: 13

QED Weighted: 0.62

Np Likeness Score: -0.42

References

1. Davison G, Martin MP, Turberville S, Dormen S, Heath R, Heptinstall AB, Lawson M, Miller DC, Ng YM, Sanderson JN, Hope I, Wood DJ, Cano C, Endicott JA, Hardcastle IR, Noble MEM, Waring MJ..  (2022)  Mapping Ligand Interactions of Bromodomains BRD4 and ATAD2 with FragLites and PepLites─Halogenated Probes of Druglike and Peptide-like Molecular Interactions.,  65  (22.0): [PMID:36367089] [10.1021/acs.jmedchem.2c01357]

Source

Source(1):

• Scientific Literature